Xie Yan, Luo Huilin, Duan Jingze, Hong Chao, Ma Ping, Li Guowen, Zhang Tong, Wu Tao, Ji Guang
Research Center for Health and Nutrition, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Teaching and Experimental Center, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Fitoterapia. 2014 Mar;93:216-25. doi: 10.1016/j.fitote.2014.01.013. Epub 2014 Jan 21.
Total flavones of Hippophae rhamnoides L. (TFH) have a clinical use in the treatment of cardiac disease. The pharmacological effects of TFH are attributed to its major flavonoid components, isorhamnetin, kaempferol, and quercetin. However, poor oral bioavailability of these flavonoids limits the clinical applications of TFH. This study explores phytic acid (IP6) enhancement of the oral absorption in rats of isorhamnetin, kaempferol, and quercetin in TFH.
In vitro Caco-2 cell experiments and in vivo pharmacokinetic studies were performed to investigate the effects of IP6. The aqueous solubility and lipophilicity of isorhamnetin, quercetin, and kaempferol were determined with and without IP6, and mucosal epithelial damage resulting from IP6 addition was evaluated by MTT assays and morphology observations.
The Papp of isorhamnetin, kaempferol, and quercetin was improved 2.03-, 1.69-, and 2.11-fold in the presence of 333 μg/mL of IP6, respectively. Water solubility was increased 22.75-, 15.15-, and 12.86-fold for isorhamnetin, kaempferol, and quercetin, respectively, in the presence of 20mg/mL IP6. The lipophilicity of the three flavonoids was slightly decreased, but their hydrophilicity was increased after the addition of IP6 in the water phase as the logP values of isorhamnetin, kaempferol, and quercetin decreased from 2.38±0.12 to 1.64±0.02, from 2.57±0.20 to 2.01±0.04, and from 2.39±0.12 to 1.15±0.01, respectively. The absorption enhancement ratios were 3.21 for isorhamnetin, 2.98 for kaempferol, and 1.64 for quercetin with co-administration of IP6 (200 mg/kg) in rats. In addition, IP6 (200 mg/kg, oral) caused neither significant irritation to the rat intestines nor cytotoxicity (400 μg/mL) in Caco-2 cells.
The oral bioavailability of isorhamnetin, kaempferol, and quercetin in TFH was enhanced by the co-administration of IP6. The main mechanisms are related to their enhanced aqueous solubility and permeability in the presence of IP6. In summary, IP6 is a potential absorption enhancer for pharmaceutical formulations that is both effective and safe.
沙棘总黄酮(TFH)在心脏病治疗中具有临床应用价值。TFH的药理作用归因于其主要黄酮类成分异鼠李素、山柰酚和槲皮素。然而,这些黄酮类化合物口服生物利用度差限制了TFH的临床应用。本研究探讨植酸(IP6)对TFH中异鼠李素、山柰酚和槲皮素在大鼠体内口服吸收的增强作用。
进行体外Caco-2细胞实验和体内药代动力学研究以考察IP6的作用。测定有无IP6存在时异鼠李素、槲皮素和山柰酚的水溶性和脂溶性,并通过MTT法和形态学观察评估添加IP6导致的黏膜上皮损伤。
在存在333μg/mL IP6时,异鼠李素、山柰酚和槲皮素的表观渗透系数(Papp)分别提高了2.03倍、1.69倍和2.11倍。在存在20mg/mL IP6时,异鼠李素、山柰酚和槲皮素的水溶性分别增加了22.75倍、15.15倍和12.86倍。三种黄酮类化合物的脂溶性略有降低,但在水相中添加IP6后其亲水性增加,因为异鼠李素、山柰酚和槲皮素的logP值分别从2.38±0.12降至1.64±0.02、从2.57±0.20降至2.01±0.04、从2.39±0.12降至1.15±0.01。在大鼠中联合给予IP6(200mg/kg)时,异鼠李素、山柰酚和槲皮素的吸收增强率分别为3.21、2.98和1.64。此外,IP6(200mg/kg,口服)对大鼠肠道既无明显刺激,对Caco-2细胞也无细胞毒性(400μg/mL)。
联合给予IP6可提高TFH中异鼠李素、山柰酚和槲皮素的口服生物利用度。主要机制与IP6存在时它们水溶性和通透性的增强有关。总之,IP6是一种有效且安全的潜在药物制剂吸收增强剂。